Teladoc Health, Inc. (NYSE:TDOC) Shares Bought by Toronto Dominion Bank

Toronto Dominion Bank increased its holdings in Teladoc Health, Inc. (NYSE:TDOC) by 33.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 21,155 shares of the health services provider’s stock after buying an additional 5,305 shares during the period. Toronto Dominion Bank’s holdings in Teladoc Health were worth $3,518,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Princeton Global Asset Management LLC acquired a new position in shares of Teladoc Health in the 2nd quarter valued at about $30,000. Psagot Investment House Ltd. acquired a new position in shares of Teladoc Health in the 2nd quarter valued at about $30,000. Gables Capital Management Inc. acquired a new position in shares of Teladoc Health in the 2nd quarter valued at about $33,000. PARK CIRCLE Co acquired a new position in shares of Teladoc Health in the 2nd quarter valued at about $33,000. Finally, Marshall Wace North America L.P. acquired a new position in shares of Teladoc Health in the 1st quarter valued at about $35,000. 79.43% of the stock is owned by institutional investors and hedge funds.

Teladoc Health stock opened at $136.02 on Thursday. The firm’s 50 day simple moving average is $138.60 and its 200-day simple moving average is $152.83. The company has a market cap of $21.66 billion, a P/E ratio of -23.99 and a beta of 0.24. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.00 and a quick ratio of 3.79. Teladoc Health, Inc. has a fifty-two week low of $120.67 and a fifty-two week high of $308.00.

Teladoc Health (NYSE:TDOC) last released its earnings results on Tuesday, July 27th. The health services provider reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.27). The firm had revenue of $503.14 million during the quarter, compared to analysts’ expectations of $499.85 million. Teladoc Health had a negative return on equity of 1.29% and a negative net margin of 46.86%. The business’s revenue was up 108.7% on a year-over-year basis. During the same period last year, the business earned ($0.34) earnings per share. On average, analysts expect that Teladoc Health, Inc. will post -3.53 EPS for the current fiscal year.

A number of research analysts have issued reports on the stock. Needham & Company LLC reduced their target price on shares of Teladoc Health from $235.00 to $205.00 and set a “buy” rating for the company in a research note on Wednesday, July 28th. Cowen reduced their target price on shares of Teladoc Health from $240.00 to $188.00 and set an “outperform” rating for the company in a research note on Monday, August 9th. KeyCorp reduced their target price on shares of Teladoc Health from $220.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, July 28th. Craig Hallum reduced their target price on shares of Teladoc Health from $202.00 to $165.00 and set a “hold” rating for the company in a research note on Wednesday, July 28th. Finally, Oppenheimer reduced their target price on shares of Teladoc Health from $250.00 to $220.00 and set an “outperform” rating for the company in a research note on Wednesday, July 28th. Twelve analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Teladoc Health has a consensus rating of “Buy” and a consensus price target of $217.75.

In other Teladoc Health news, COO David William Sides sold 3,420 shares of the business’s stock in a transaction that occurred on Friday, July 30th. The shares were sold at an average price of $154.38, for a total value of $527,979.60. Following the completion of the sale, the chief operating officer now directly owns 14,451 shares of the company’s stock, valued at $2,230,945.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jason N. Gorevic sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 3rd. The stock was sold at an average price of $150.12, for a total transaction of $1,501,200.00. The disclosure for this sale can be found here. Insiders have sold 17,470 shares of company stock worth $2,609,504 over the last ninety days. 6.47% of the stock is currently owned by insiders.

About Teladoc Health

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

See Also: Cash Flow

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.